PR View by Ilyssa Levins

Why should marketers allocate more help-seeking DTC spending to PR?

DTC PR boosts the ROI of disease-awareness advertising with minimal investment.  A $4 million to $6 million PR campaign delivers a significant level of disease-state media relations and educational events in partnership with advocacy groups, complete with direct response mechanisms such as Web  site address, toll-free phone number and PO Box. That's a drop in the proverbial bucket for a DTC advertising budget.

DTC PR cost helps build patient databases by delivering messages that are more convincing than DTCA, because independent sources (media and third-party organizations) are believed and trusted by consumers.

PR can also deliver disease-state messages more effectively to multicultural populations, which often do not receive medical information through traditional channels but rather from clergy and other community-based sources.

PR drives people into databases, where questions are asked, information is dispatched and names are captured. At some point in the dialogue, an opt-in query is made, and upon receiving the patient's consent, the company has the chance to communicate its product messages.

Now for the bonus points. PR helps sister media improve the bottom line and patients' lives. Research shows that knowledge about disease states and therapeutic options is a critical component of patient-centered healthcare practices. Highly involved patients are more adherent to treatment regimens, increasing drug utilization and patient outcomes.

In addition, PR can help promote the strong evidence of pharma's commitment to the public good at a time when the industry's reputation is at an all-time low and media skepticism at an all-time high.

Ilyssa Levins is president of HCIL Consulting

You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.